KPF
IMVT icon

K2 Principal Fund’s Immunovant IMVT Stock Holding History

K2 Principal Fund’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-102,926
Closed -$1.01M – 330
2019
Q3 		$1.01M Buy
+102,926
New +$1.02M 0.11% 205

Other funds holding IMVT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AC
Athanor Capital New York $24.6M AUM 2.49% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

K2 Principal Fund's IMVT Position: Q4 2019 in Review

K2 Principal Fund sold out of Immunovant (IMVT) in Q4 2019, closing a stake of 102,926 shares — an estimated $1.01M sold.

K2 Principal Fund first reported a position in IMVT in Q3 2019 and held it in 1 quarter. The position peaked at $1.01M in Q3 2019. 24 funds tracked by Wall St. Rank hold IMVT as of Q4 2019.

  • K2 Principal Fund reported no remaining Immunovant position as of Q4 2019 after selling out during the quarter.
  • K2 Principal Fund sold 102,926 Immunovant shares in Q4 2019, an estimated $1.01M.
  • K2 Principal Fund first reported a position in Immunovant in Q3 2019 and held it in 1 quarter.
  • K2 Principal Fund's Immunovant position peaked at $1.01M in Q3 2019.
  • 24 funds tracked by Wall St. Rank held Immunovant as of Q4 2019.

Based on K2 Principal Fund's 13F filing for Q4 2019, filed 13 Feb 2020.